(NASDAQ: ENSC) Ensysce Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.46%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 184.56%.
Ensysce Biosciences's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast ENSC's revenue for 2026 to be $72,867,990, with the lowest ENSC revenue forecast at $70,010,422, and the highest ENSC revenue forecast at $75,011,167.
In 2027, ENSC is forecast to generate $826,301,116 in revenue, with the lowest revenue forecast at $793,893,694 and the highest revenue forecast at $850,609,002.